History of Aurobindo Pharma Ltd.
1986
- The Comp. was incorporated on 26th December as a Private Limited company & was converted into a Public Limited Comp. with effect from 30-4-1992. The Comp. is registered with the Registrar of Companies, Andhra Pradesh at Hyderabad. The chief promoters of the Company are Shri P.V. Ramaprasad Reddy & Shri K. Nityananda Reddy.
- Aurobindo Pharma Limited is one of leading manufacturers of life saving anti-biotic bulk drugs in India with excellent track record of profitability & growth.
- The Comp. has developed inhouse technology for manufacture of the bulk drugs as well as formulations.
- The Comp. is one of largest manufacturers of Ampicillin and Cloxacillin in India.
1992
- Another unit was also set up for manufacture of CMIC Chloride, a bulk drug intermediate at Pashamylaram, near Hyderabad. Through another Comp. namely, Chaitanya Organics Pvt. Ltd., which is now being merged with Aurobindo Pharma Limited.
- The Comp. issued Bonus Shares in the ratio of 1:1 in May, in the ratio of 2:1 in June, 1993 & in the ratio of 7:20, in November 1994.
- The Comp. follows the Mercantile System of Accounting and recognises Income & Expenditure on Accrual basis.
1993
- The Comp. has set up two more units during the year, viz.,
- is] Bulk drug unit at Bollaram, near Hyderabad.
- iis] Formulations unit at Kukatpally, near Hyderabad.
- The Comp. is setting up a Bulk Drug cum Formulation Plant to produce sterile Bulk Drugs like Ampicillin Sodium [Steriles] IP/BP, Cloxacillin Sodium [Steriles] IP/BP, & cephalosporins [Steriles] Bulk Drugs & Formulations in the dosage forms like sterile powder injectables, small volume parenterals, Capsules & Tablets.
1994
- The installed capacity of Pondicherry Unit of Comp. is increased from 204 TPA to 300 TPA during the current year
- The Bollaram unit is for manufacture of anti-biotic bulk drugs, namely Cloxacillin, & Dicloxacillin mainly for exports.
- During the Year, the Comp. has upgraded the plant & increased the installed capacity from 78 TPA to 84 TPA. The Comp. has set up a separate block in the same premises during the current year, 1994-95 for manufacture of high value drugs namely Astemizole, Domeperidone, Famotidine & Omeprazole, with an installed capacity of 9 TPA.
- The Kukatpally unit is for manufacture of pharmaceutical formulations with an installed capacity of 360 lakhs tablets & 480 lakhs capsules per annum.
- During the current year the Comp. has increased the installed capacity of merged Comp. Chaitanya Organics Pvt. Ltd., from 120 TPA to 144 TPA. Further a new bulk drug intermediate namely DCMIC Chloride is also manufactured in this unit from April. The Comp. has also expanded the above unit by setting up a separate block for manufacture of Norfloxacillin & Pefloxacillin with an installed capacity of 60 TPA.
- The Comp. proposed to acquire two generators of 250 KVA capacity each as standby arrangement.
- The Comp. has entered into domestic formulations market in 5 States and plans to launch in other states shortly.
- The Comp. has agency set-up at Srilanka, Thailand, Russia and Nigeria for marketing its products. It proposes to set up its own marketing offices at Hongkong, Moscow & Nigeria to promote bulk drug sales.
- The Comp. has a connected power load of 500 KVA from A.P.S.E.B. In addition, 3 Generators of 125 KVA capacity each have been installed as a stand by arrangement.
- The Comp. is a member of Patancheru Effluent Treatment Plant Limited & Jeedimetle Effluent Treatment Plant.
- All the Assets & Liabilities of M/s. Chaitanya Organics Pvt. Ltd. will be taken over by M/s. Aurobindo Pharma limited with effect from 1st April, on completion of amalgamation formalities.
- As per the scheme of amalgamation it is proposed to issue one equity share of M/s. Aurobindo Pharma limited of Rs 10/- each credited as fully paid up for every one equity share of Rs 10/- each fully paid up held in M/s. Chaitanaya Organics Pvt. limited to the Shareholders of M/s. Chaitanya Organics Pvt. Ltd.
1995
- In January, Videocon International & Videocon Appliances sold a tranche of Aurobindo shares to the public at a premium of Rs 180.
1997
- Glaxo [Indias], the Indian subsidiary of UK-based multinational, is understood to be negotiating with the Hyderabad-based Aurobindo Pharma for an alliance to meet its global bulk drug requirements.
- The annual capacities now stand at 300 million of capsules & 840 tonnes of bulk drugs.
- The Comp. proposes to manufacture fourth generation cephalosporins such as 7-ACA, cephalexin, cephatoxime & cephazolin.
1998
- AUROBINDO Pharma Ltd is setting up two wholly-owned subsidiaries in the US & Hong Kong to increase its presence in the international market.
- The Comp. is one of largest bulk manufacturers of semi-synthetic penicillin [SSPs] products such as ampicilin and Amoxycillin. It is the world fourth largest producer of ampicillins and fifth largest producer of amoxycillins.
- The Comp. has also launched new formulations like auronim Suspension in the paediatric segment.
- The Comp. has obtained the shareholders permission to invest $2,00,000 in the share capital of Aurobindo Pharma [Miamis] Inc in USA and $150,000 in the share capital of Aurobindo Pharma [Hong Kongs] Pte Ltd.
- The Comp. would be launching several new formulations including Roxythromycin, Clarithromycin, Sporfloxocyin, besides Sephradin, a smei-synthetic, in the domestic market. Among sterile products to be launched by Comp. are Cephazolin, Cehatoxin & Azithromycin.
1999
- The Hyderabad-based Aurobindo Pharma had received in-principle approval from the Board of Industrial & Financial Reconstruction [BIFRs] in March to buy the plant.
- APL is today the most cost-efficient producer of SSPs in India & a low cost international producer of other value added bulk drugs and drug intermediaries.
- Aurobindo currently manufactures three types of drugs including cephalosporin-based formulations, drugs for gastroenterology and pain-related products.
- The Comp. proposes to deploy the issue proceeds to part-finance its R&D thrust & the growth of its formulations business. APL plans to meet the further funds requirement for its capital expenditure programme, if any, through internal accruals.
- The board of directors has allotted 5,51,000 equity shares of Rs.10 each at a premium of Rs.480 per share by private placement on preferential basis to FIIs, FIs, MFs & bodies corporate etc.
- Aurobindo Pharma Ltd, the largest domestic manufacturer of penicillin-based bulk antibiotics, plans to form joint ventures in Brazil & China by end of financial year 1999-2000 [April-Marchs].
2000
- Aurobindo Pharma limited a major producer of semi-synthetic penicillins in the country, proposes to set up two joint venture companies in the US to manufacture cephalosporins & non-cephalosporins.
- Aurobindo Pharma is setting up two joint ventures for formulations in the US, with an investment of $12 million.
- As per the scheme of Amalgamation equity shares of Aurobindo Pharma Limited will be exchanged to the shareholders of Sri Chakra Remedies Limited for every 100 equity shares held by them.
2001
- The Comp. has launched an exclusive anti-viral division -- Immunus -- to educate & to provide preventive drug care for HIV/AIDS patients in the country.
- Hyderabad based Aurobindo Pharma has restructured its management responsibilities in view of major growth initiatives to be taken to create a platform for penetrating attractive global markets. P V Ramaprasad Reddy, former managing director, has been appointed executive chairman, while K Nityananda Reddy, former joint managing director & co-promoter, has been appointed managing director, APL informed the Bombay Stock Exchange on July 4.
-This new structure is expected to enable the Comp. to concentrate on the 'strategies of change' being pursued by it to achieve the goal of becoming a research & development-based international pharmaceutical company, it said, adding that the changes had received board approval.
-Aurobindo Pharma Ltd today announced the launch two more drugs-- Efavirenz [Viranzs] & Nelfinavir [NELVEXs]-- for treatment of AIDS.
2002
-Three existing Directors, Mr Srinivas Lanka, Mr A J Kamath & Mr A Siva Rama Prasad have stepped down from the directorship, thus making room for appointment of independent external directors. Accordingly, their resignations were accepted. While Mr Srinivas Lanka will be considered for reappointment as non-executive independent Director, Mr A J Kamath will assume the responsibility of group financial advisor. Further, it is planned to retain the services of Mr A Siva Rama Prasad for group operations.
-Aurobindo Pharma to allot further equity shares/warrants to promoters.
-Srinivas Lanka re-inducted into the Board of Aurobindo Pharma.
-Sathyamurthy appointed as Additional Director of Aurobindo Pharma.
2003
-The Board of Directors of Aurobindo Pharma Ltd has approved the appointment of Dr K A Balasubramanian as an additional director on the Board of Directors of company. Dr Balasubramanian shall be an independent, non-executive director.
-Aurobindo informed BSE that Citadel Aurobindo Biotech Ltd, a 50:50 Joint venture company introduced Aztreonam a Monabactam Betalactam antibiotic for first time in the Indian Pharma Market with a brand name 'TREONAM'.
-Aurobindo Tongling [Datongs] pharmaceuticals Ltd, China , a JV between APL & Shanxi Tongling Pharmaceuticals co. has set up for manufacture of pharmaceutical products for local market.
-With a view to manufacture Pen G, a raw material essential for production of semi-synthrtic pencillin, Aurobindo has infused Rs 59cr in a flagship Aurobindo[Datongs] Pharma Ltd.
-Aurobindo Pharma has launched second joint venture Comp. in US for purpose of Research & Development.
-Allots 950,000 equity shares to promoters/directors by way of conversion of warrants
-Aurobindo Pharma has launched second joint venture Comp. in the United States for purpose of R and D in alliance with Salus Pharmaceuticals.
-Aurobindo Pharma has filed around 20 patents in the areas of central nervous system, cardio-vascular, & anti-cholesterol segments. Out of this it is able to obtain 2 of them in United States of America.
-UTI sold 3 pc stake from the company
-Board approves the issue on a preferential basis, of an aggregate upto 3,100,000 equity shares of Rs.5/- each at a price of Rs.302/- per equity share [including a premium of Rs.297 per equity shares], totalling up to Rs.93.62 cr
-Company ropes in Merlion India Fund 1, Mauritius, for allotting 31 lakh equity shares on a preferential basis at a price of Rs 302 per share, including a premium of Rs 297 per share, totalling Rs 93.62 crore
2004
- Ms P. Suneela Rani, has sold 6,80,000 equity shares of Rs 5 each of company, constituting 1.4 per cent of equity of its current paid-up equity of Rs 24.2 crore. These shares were sold in the open market from December 23-31 last year
Aurobindo Pharma Ltdhas announced that it has received its first Certificate of Suitability [CoSs] approval from the European Directorate for Quality Medicines [EDQMs] for its product in the therapeutic segment of gastroenterology.
-Aurobindo Pharma Ltd has informed that the members at the EGM of Comp. held on December 26, 2003 have unanimously approved the following special resolution : 'Issue of equity shares under preferential allotment guidelines of SEBI'. Further, the Comp. has also informed that delisting of securities of Comp. from Ahmedabad Stock Exchange was approved w.e.f. January 15, 2004.
-Aurobindo Pharma Ltd has informed that pursuant to the application of Company, its securities have been removed from the list of Ahmedabad Stock Exchange [ASEs] w.e.f. January 15, 2004.
2005
-USFDA part of Department of health & human science approves UNIT VIII facility as a site to manufacture APIs for US Market.
-Aurobindo AIDS drug receives US FDA clearance
-Aurobindo Pharma gets EDQM approval for Flucloxacillin Sodium
-Aurobindo Pharma receives approval for Sertraline Hydrochloride Tablets
-Aurobindo Pharma receives approval for Cephalexin Capsules by US FDA
-Aurobindo receives final approval of Mirtazapine Orally Disintegrating Tablets
2006
-Aurobindo Pharma receives final approval of Mirtazapine ODT 45mg for US marketAurobindo Pharma receives final approval of Mirtazapine ODT 45mg for US market
-Aurobindo Pharma Ltd has announced that the US FDA has granted tentative approval for Company Simvastatin Tablets USP 5 mg, 10 mg, 20 mg, 40 mg & 80 mg
-Aurobindo receives US FDA approval for Didanosine [Chewables] Tablets -Aurobindo Pharma Ltd has announced that it has received the marketing authorization approval from Medicines Evaluation Board [MEBs], NETHERLANDS for Mirtazapine 15, 30 & 45 mg orally disintegrating tablets containing the active ingredient Mirtazapine.
-Aurobindo Pharma Ltd has appointed Mr. A.Mohan Rami Reddy as Comp. Secretary of Company.
-Aurobindo Pharma receives final approval for SIMVASTATIN tablets from USFDA.
-Aurobindo arm acquires Dutch firm Pharmacin.
2007
- Aurobindo Pharma Ltd has received one more approval from USFDA for Cefadroxil capsules 500 mg.
- Aurobindo Pharma Ltd has announced that on June 13, 2007 the Comp. unveiled their new Logo & Corporate Identity at a ceremony in Hyderabad.
2008
- Aurobindo Pharma Ltd has announced that the Comp. has received an approval from the US Food and Drug Administration to market its 300mg Cefdinir Capsules in the US market. The drug falls under the Anti-bacterial segment & is a generic equivalent of Abbott Laboratories, OMNICEF.
-Aurobindo Pharma Ltd has appointed Mr. K Raghunathan as an Additional Director of Comp. at the Board Meeting held on January 30, 2008.
- Aurobindo Pharma Ltd has announced that the Comp. has been awarded ARV contract worth Rs 70 crores for 3 products which are WHO / USFDA pre-qualified by National Aids Control Organization [NACOs].
- Aurobindo Pharma Ltd has got final clearance from the US Food & Drug Administration [USFDAs] to manufacture & market Didanosine Delayed Release capsules in 125 mg, 200 mg, 250 mg & 400 mg. The drug is indicated for treatment of HIV - 1 infections in adults. It is the generic version of Bristol Myer Squibb Videx EC delayed-release capsules.
